查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607977

骨髓恶性肿瘤市场：按类型、治疗、诊断、最终用户分类 - 全球预测 2025-2030

Hematological Malignancies Market by Types (Leukemia, Lymphoma, Multiple Myeloma), Treatment (Bone Marrow Transplantation, Chemotherapy, Chimeric Antigen Receptor (Car) T Cell Therapy), Diagnosis, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

骨髓恶性肿瘤市场2023年估值为153.3亿美元，预计到2024年将达到168.4亿美元，复合年增长率为9.92%，到2030年将达到297.3亿美元。

骨髓恶性肿瘤包括多种与血液相关的癌症，包括白血病、淋巴瘤和多发性骨髓瘤。其范围包括阐明疾病机制、改进诊断方法和开发新治疗方法。这些癌症的盛行率不断上升以及分子生物学和基因组学的进步凸显了对创新治疗策略和准确诊断的需求。最终用途涵盖製药、生物技术和诊断领域，包括医院、研究机构和专科诊所。该市场受到癌症研究资金增加、个人化医疗进步以及标靶治疗研究和开发等因素的支持。机会包括 CAR-T 细胞疗法的出现、基于 RNA 的治疗方法的扩展以及有望实现个人化治疗方法的次世代定序的进步。对毒性更低、更有效的治疗方法的需求也推动了免疫疗法和联合治疗的研究。然而，高昂的治疗成本、严格的监管环境以及临床试验的复杂性等挑战构成了重大障碍。我们还需要解决与现有疗法相关的抗药性和副作用。策略建议包括投资于早期研究伙伴关係以及促进与学术机构的合作以加速创新。基因编辑技术（如 CRISPR）和液态切片等领域的开拓有可能进一步彻底改变诊断和监测。市场竞争依然激烈，研发不断将经济高效且可扩展的解决方案推向前线。透过专注于改善患者资料整合和数位健康干预措施，我们可以改善患者治疗结果并简化临床试验流程。市场的本质是动态的，不断转向基于价值的护理并强调整体患者管理。为了保持竞争优势，公司必须优先考虑适应性，投资新技术，并不断回应医疗保健提供者和患者不断变化的需求。

主要市场统计
基准年[2023] 153.3亿美元
预计年份 [2024] 168.4亿美元
预测年份 [2030] 297.3亿美元
复合年增长率（%） 9.92%

市场动态：快速发展的骨髓恶性肿瘤市场的关键市场洞察

供需的动态交互作用正在改变骨髓恶性肿瘤市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 血癌患者增加
    • 提高对早期诊断可能性的认识
    • 有利的法规环境和政府对治疗的支持
  • 市场限制因素
    • 缺乏与骨髓恶性肿瘤治疗相关的认知和高昂的费用
  • 市场机会
    • 增加对开发先进骨髓恶性肿瘤的投资
    • 骨髓恶性肿瘤治疗新药核准上市数量快速增加
  • 市场挑战
    • 骨髓恶性肿瘤治疗药物缺乏熟练专业人员和副作用

波特五力：驾驭骨髓恶性肿瘤市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解骨髓恶性肿瘤市场的外部影响

外部宏观环境因素在塑造骨髓恶性肿瘤市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解骨髓恶性肿瘤市场的竞争格局

骨髓恶性肿瘤市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵骨髓恶性肿瘤市场供应商的绩效评估

FPNV 定位矩阵是评估骨髓恶性肿瘤市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了骨髓恶性肿瘤市场的成功之路

骨髓恶性肿瘤市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 血癌发生率增加
      • 提高对早期诊断可能性的认识
      • 有利的法规环境和政府对治疗方法的支持
    • 抑制因素
      • 对骨髓恶性肿瘤治疗缺乏认识且费用庞大
    • 机会
      • 增加对开发先进骨髓恶性肿瘤的投资
      • 新药核准上市数量快速增加
    • 任务
      • 缺乏熟练的专业人员和骨髓恶性肿瘤治疗的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章骨髓恶性肿瘤市场：依类型

  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤

第七章依治疗分類的骨髓恶性肿瘤市场

  • 骨髓移植
  • 化疗
  • 嵌合体抗原受体 (Car) T 细胞疗法
  • 免疫疗法
  • 标靶治疗

第八章骨髓恶性肿瘤诊断市场

  • 切片检查
  • 验血
  • 影像检查

第九章骨髓恶性肿瘤市场：依最终用户分类

  • 居家护理
  • 医院
  • 专科诊所

第10章美洲骨髓恶性肿瘤市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太骨髓恶性肿瘤市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲/中东/非洲骨髓恶性肿瘤市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Adaptimmune Limited
  • Adcendo ApS
  • Amgen Inc.
  • Artiva Biotherapeutics, Inc.
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Dren Bio, Inc.
  • F. Hoffmann-La Roche AG
  • Geron Corporation
  • GlaxoSmithKline PLC
  • Harpoon Therapeutics, Inc.
  • Immune-Onc Therapeutics, Inc.
  • Interius BioTherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Kirilys Therapeutics, Inc.
  • Kymera Therapeutics
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Moleculin Biotech, Inc.
  • NovalGen Ltd.
  • Novartis AG
  • Oncoternal
  • Pfizer Inc.
  • Prelude Therapeutics Incorporated
  • Reverie Labs Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • TG Therapeutics, Inc.
  • Tvardi Therapeutics, Inc.
Product Code: MRR-C002B1C994F0

The Hematological Malignancies Market was valued at USD 15.33 billion in 2023, expected to reach USD 16.84 billion in 2024, and is projected to grow at a CAGR of 9.92%, to USD 29.73 billion by 2030.

Hematological malignancies encompass a diverse group of blood-related cancers, including leukemia, lymphoma, and multiple myeloma. The scope involves understanding disease mechanisms, improving diagnostics, and developing novel therapies. The rising incidence of these cancers and advances in molecular biology and genomics underline the necessity of innovative therapeutic strategies and precise diagnostics. The application spans pharmaceuticals, biotechnology, and diagnostic sectors, with end-use across hospitals, research institutes, and specialty clinics. The market is buoyed by factors like increased funding for cancer research, advancements in personalized medicine, and the development of targeted therapies. Opportunities arise from the emergence of CAR-T cell therapies, expanding RNA-based treatments, and advancements in next-generation sequencing, which promise personalized treatment regimens. The demand for less toxic and more efficient treatments has also catalyzed research into immunotherapies and combination treatments. However, challenges such as high treatment costs, stringent regulatory landscapes, and the complexity of clinical trials pose significant hindrances. There's also a need to address drug resistance and the adverse effects associated with existing therapies. Strategic recommendations include investing in early-stage research partnerships and fostering collaboration with academic institutions to accelerate innovation. Exploring areas like gene editing technologies (e.g., CRISPR) and liquid biopsies could further revolutionize diagnostics and monitoring. The market remains highly competitive, with sustained R&D to bring cost-effective and scalable solutions to the forefront. Focused efforts on improving patient data integration and digital health interventions can enhance patient outcomes and streamline clinical trial processes. The nature of the market is dynamic, with ongoing shifts towards value-based care and emphasis on holistic patient management. To maintain competitive advantage, businesses should prioritize adaptability, invest in emerging technologies, and continuously address the evolving needs of healthcare providers and patients within the hematological malignancies landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 15.33 billion
Estimated Year [2024] USD 16.84 billion
Forecast Year [2030] USD 29.73 billion
CAGR (%) 9.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hematological Malignancies Market

The Hematological Malignancies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of hematological cancer cases
    • Rising awareness about the possibility of early diagnosis
    • Favorable regulatory environment and government support for therapies
  • Market Restraints
    • Lack of awareness and huge cost associated with hematological malignancies treatment
  • Market Opportunities
    • Rising investment in the development of advanced hematological malignancies treatment
    • Surging drug approvals and launches of novel hematological malignancies drugs
  • Market Challenges
    • Dearth of skilled professionals and side effects of hematological malignancies therapies

Porter's Five Forces: A Strategic Tool for Navigating the Hematological Malignancies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hematological Malignancies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hematological Malignancies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hematological Malignancies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hematological Malignancies Market

A detailed market share analysis in the Hematological Malignancies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hematological Malignancies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hematological Malignancies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hematological Malignancies Market

A strategic analysis of the Hematological Malignancies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hematological Malignancies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Limited, Adcendo ApS, Amgen Inc., Artiva Biotherapeutics, Inc., Atara Biotherapeutics, Inc., Bristol-Myers Squibb Company, Dren Bio, Inc., F. Hoffmann-La Roche AG, Geron Corporation, GlaxoSmithKline PLC, Harpoon Therapeutics, Inc., Immune-Onc Therapeutics, Inc., Interius BioTherapeutics, Inc., Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Kirilys Therapeutics, Inc., Kymera Therapeutics, MEI Pharma, Inc., Merck & Co., Inc., Moleculin Biotech, Inc., NovalGen Ltd., Novartis AG, Oncoternal, Pfizer Inc., Prelude Therapeutics Incorporated, Reverie Labs Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, TG Therapeutics, Inc., and Tvardi Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Hematological Malignancies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Types, market is studied across Leukemia, Lymphoma, and Multiple Myeloma.
  • Based on Treatment, market is studied across Bone Marrow Transplantation, Chemotherapy, Chimeric Antigen Receptor (Car) T Cell Therapy, Immunotherapy, and Targeted Therapy.
  • Based on Diagnosis, market is studied across Biopsy, Blood Tests, and Imaging Tests.
  • Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of hematological cancer cases
      • 5.1.1.2. Rising awareness about the possibility of early diagnosis
      • 5.1.1.3. Favorable regulatory environment and government support for therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness and huge cost associated with hematological malignancies treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising investment in the development of advanced hematological malignancies treatment
      • 5.1.3.2. Surging drug approvals and launches of novel hematological malignancies drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of skilled professionals and side effects of hematological malignancies therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hematological Malignancies Market, by Types

  • 6.1. Introduction
  • 6.2. Leukemia
  • 6.3. Lymphoma
  • 6.4. Multiple Myeloma

7. Hematological Malignancies Market, by Treatment

  • 7.1. Introduction
  • 7.2. Bone Marrow Transplantation
  • 7.3. Chemotherapy
  • 7.4. Chimeric Antigen Receptor (Car) T Cell Therapy
  • 7.5. Immunotherapy
  • 7.6. Targeted Therapy

8. Hematological Malignancies Market, by Diagnosis

  • 8.1. Introduction
  • 8.2. Biopsy
  • 8.3. Blood Tests
  • 8.4. Imaging Tests

9. Hematological Malignancies Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Hematological Malignancies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hematological Malignancies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hematological Malignancies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adaptimmune Limited
  • 3. Adcendo ApS
  • 4. Amgen Inc.
  • 5. Artiva Biotherapeutics, Inc.
  • 6. Atara Biotherapeutics, Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Dren Bio, Inc.
  • 9. F. Hoffmann-La Roche AG
  • 10. Geron Corporation
  • 11. GlaxoSmithKline PLC
  • 12. Harpoon Therapeutics, Inc.
  • 13. Immune-Onc Therapeutics, Inc.
  • 14. Interius BioTherapeutics, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Karyopharm Therapeutics Inc.
  • 17. Kirilys Therapeutics, Inc.
  • 18. Kymera Therapeutics
  • 19. MEI Pharma, Inc.
  • 20. Merck & Co., Inc.
  • 21. Moleculin Biotech, Inc.
  • 22. NovalGen Ltd.
  • 23. Novartis AG
  • 24. Oncoternal
  • 25. Pfizer Inc.
  • 26. Prelude Therapeutics Incorporated
  • 27. Reverie Labs Inc.
  • 28. Sanofi S.A.
  • 29. Takeda Pharmaceutical Company Limited
  • 30. TG Therapeutics, Inc.
  • 31. Tvardi Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. HEMATOLOGICAL MALIGNANCIES MARKET RESEARCH PROCESS
  • FIGURE 2. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEMATOLOGICAL MALIGNANCIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEMATOLOGICAL MALIGNANCIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMATOLOGICAL MALIGNANCIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMATOLOGICAL MALIGNANCIES MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 193. HEMATOLOGICAL MALIGNANCIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. HEMATOLOGICAL MALIGNANCIES MARKET, FPNV POSITIONING MATRIX, 2023